Masimo (MASI) reported $492.8 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 12.8%. EPS of $0.77 for the same period compares to $0.87 a year ago.The reported revenue represents a surprise of +0.95% over the Zacks Consensus Estimate of $488.18 million. With the consensus EPS estimate being $0.71, the EPS surprise was +8.45%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street exp ...

First Quarter 2024 Highlights: Exhibit 99.1 Masimo Reports First Quarter 2024 Financial Results Irvine, California, May 7, 2024 - Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Results: Consolidated revenue was $492.8 million, comprised of healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and inst ...

Billionaire Masimo founder Joe Kiani, best known for his successful legal fight against Apple and his friendship with President Joe Biden, has borrowed against half of his $660 million stake in the health-technology company rather than sell his stock, according to corporate filings from earlier this week.Borrowing against that much of a stake is unusual for executives, but may be helpful as the company prepares for a fight with an activist aiming to take control of the board. The move allows Kiani, the comp ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Masimo (MASI) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.When looking at the last two reports, this medical technology company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 19.18%, on average, in the last two quarters.For the last reported quar ...

Masimo Corporation (MASI) is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) efforts. The optimism led by a solid fourth-quarter 2023 performance and its solid product portfolio are expected to contribute further. However, concerns regarding overdependence on its Signal Extraction Technology (SET) and macroeconomic concerns persist.Over the past year, this Zacks Rank #3 (Hold) stock has lost 30% compared with the industry’s 0.4% decline. The S&P 500 has witnesse ...

Masimo (MASI) is witnessing strong momentum, with its shares having rallied 17.9% year to date compared with 3.4% growth of the industry. The S&P 500 Composite has risen 6.3% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Headquartered in Irvine, CA, Masimo develops, manufactures and markets a family of non-invasive monitoring systems. The company derives the majority ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________ FORM 10-K ________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Com ...

Exhibit 99.1 Masimo Reports Fourth Quarter and Full-Year 2023 Financial Results Fourth Quarter 2023 Highlights: Full-Year 2023 Highlights: Irvine, California, February 27, 2024 - Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 30, 2023. Fourth Quarter 2023 Results: Consolidated revenue was $548.9 million, comprised of healthcare revenue of $339.9 million and non-healthcare revenue of $209.0 million. Excluding handheld and fingertip pulse oximet ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 For the transition period from _________ to _________ Commission File ...

Masimo Corporation (NASDAQ:MASI) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Operator However, they are subject to risks and uncertainties that could cause actual results to differ materially. Risk factors that could cause our actual results to differ materially from our projections and forecasts are discussed in detail in our periodic filings with the SEC. You will find these in the Investor Relations section of our website. Eli Kammerman - Vice President, Business Development and Investor R ...